Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma

Cancer Medicine

Volumn 4, Issue 6, 2015, Pages 871-886

  Saulnier Sholler, Giselle L ^a,b   Bond, Jeffrey P ^c   Bergendahl, Genevieve ^a   Dutta, Akshita ^a   Dragon, Julie ^c   Neville, Kathleen ^d   Ferguson, William ^e   Roberts, William ^f   Eslin, Don ^g   Kraveka, Jacqueline ^h   Kaplan, Joel ⁱ   Mitchell, Deanna ^a   Parikh, Nehal ^j   Merchant, Melinda ^k   Ashikaga, Takamaru ^c   Hanna, Gina ^g   Lescault, Pamela Jean ^l   Siniard, Ashley ^m   Corneveaux, Jason ^m   Huentelman, Matthew ^m   Trent, Jeffrey ^m   more..

^a HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ Levine Children's Hospital   (United States)

^j Division of Pediatric Infectious Diseases   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l MARINE BIOLOGICAL LABORATORY   (United States)

^m TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

more..

Author keywords

Genomic profiling; Molecular tumor board; Molecular guided therapy; Neuroblastoma; Pediatric oncology

Indexed keywords

ALANINE AMINOTRANSFERASE; AMFEBUTAMONE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; BORTEZOMIB; CYTARABINE; DOXORUBICIN; DOXYCYCLINE; LAPATINIB; MITOXANTRONE; RNA; SIMVASTATIN; SORAFENIB; TOPOTECAN; VINBLASTINE; VORINOSTAT; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BIOINFORMATICS; BLOODSTREAM INFECTION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG RESPONSE; ESOPHAGUS PAIN; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKEMIA; LEUKOPENIA; LUNG MYCOSIS; LYMPHOCYTOPENIA; MALE; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; PAIN; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RASH; RISK ASSESSMENT; RNA SEQUENCE; SIDE EFFECT; SKIN PAIN; STOMACH PAIN; SURVIVAL RATE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT PLANNING; TUMOR BIOPSY; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ADVERSE EFFECTS; CHRONIC DISEASE; CLINICAL TRIAL; EVALUATION STUDY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PATIENT SAFETY; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; TIME TO TREATMENT; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PATIENT SAFETY; PROSPECTIVE STUDIES; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TIME-TO-TREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85006198824     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.436     Document Type: Article

References (43)

1. Society AC. 2008. Cancer facts and figures. American Cancer Society, Atlanta, GA.
2. Bernstein, M. L., J. M. Leclerc, G. Bunin, L. Brisson, L. Robison, J. Shuster, et al. 1992. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J. Clin. Oncol. 10:323-329.
3. Brodeur, G. M., J. Pritchard, F. Berthold, N. L. Carlsen, V. Castel, R. P. Castelberry, et al. 1993. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11:1466-1477.
4. Park, J. R., A. Eggert, and H. Caron . 2008. Neuroblastoma: biology, prognosis, and treatment. Pediatr. Clin. North Am. 55:97-120, x.
5. Matthay, K. K., J. G. Villablanca, R. C. Seeger, D. O. Stram, R. E. Harris, N. K. Ramsay, et al. 1999. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341:1165-1173.
6. Hartmann, O., D. Valteau-Couanet, G. Vassal, V. Lapierre, L. Brugieres, R. Delgado, et al. 1999. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 23:789-795.
7. Wagner, L. M., and M. K. Danks . 2009. New therapeutic targets for the treatment of high-risk neuroblastoma. J. Cell. Biochem. 107:46-57.
8. Wei, J. S., B. T. Greer, F. Westermann, S. M. Steinberg, C. G. Son, Q. R. Chen, et al. 2004. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 64:6883-6891.
9. Pugh, T. J., O. Morozova, E. F. Attiyeh, S. Asgharzadeh, J. S. Wei, D. Auclair, et al. 2013. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45:279-284.
10. Park, J. R., R. Bagatell, W. B. London, J. M. Maris, S. L. Cohn, K. K. Mattay, et al. 2013. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr. Blood Cancer 60:985-993.
11. Shah, S., S. Weitman, A. M. Langevin, M. Bernstein, W. Furman, and C. Pratt . 1998. Phase I therapy trials in children with cancer. J. Pediatr. Hematol. Oncol. 20:431-438.
12. Nieder, C., M. Adam, M. Molls, and A. L. Grosu . 2006. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. 60:181-193.
13. Vogelstein, B., N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., and K. W. Kinzler . 2013. Cancer genome landscapes. Science 339:1546-1558.
14. Cancer Genome Atlas N. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
15. Cancer Genome Atlas Research N. 2013. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43-49.
16. Cancer Genome Atlas Research N. 2014. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322.
17. Overington, J. P., B. Al-Lazikani, and A. L. Hopkins . 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5:993-996.
18. Wishart, D. S., C. Knox, A. C. Guo, D. Cheng, S. Shrivastava, D. Tzur, et al. 2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36:D901-D906.
19. Saulnier Sholler, G. L., G. Bergendahl, E. Currier, S. R. Lenox, J. Bond, M. Slavik, et al. 2012. A pilot trial testing the feasibility of using molecular-guided therapy in patients with recurrent neuroblastoma. J. Cancer Ther. 3:602-612.
20. Webb, C. P., and D. M. Cherba . 2009. Systems biology of personalized medicine. Pp. 615-630 in S. Krawetz, ed. Bioinformatics for systems biology. Humana Press, New York, NY.
21. Von Hoff, D. D., J. J. Stephenson Jr., P. Rosen, D. M. Loesch, M. J. Borad, S. Anthony, et al. 2010. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28:4877-4883.
22. Dezso, Z., Y. Nikolsky, T. Nikolskaya, J. Miller, D. Cherba, C. Webb, et al. 2009. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst. Biol. 3:36.
23. Shi, W., M. Bessarabova, D. Dosymbekov, Z. Dezso, T. Nikolskaya, M. Dudoladova, et al. 2010. Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. Pharmacogenomics J. 10:310-323.
24. Vellaichamy, A., Z. Dezso, L. JeBailey, A. M. Chinnaiyan, A. Sreekumar, A. I. Nesvizhskii, et al. 2010. "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One 5:e10936.
25. Lamb, J., E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, et al. 2006. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935.
26. Lee, J. K., D. M. Havaleshko, H. Cho, J. N. Weinstein, E. P. Kaldjian, J. Karpovich, et al. 2007. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 104:13086-13091.
27. Gheeya, J. S., Q. R. Chen, C. D. Benjamin, A. T. Cheuk, P. Tsang, J. Y. Chung, et al. 2009. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol. Ther. 8:2386-2395.
28. Trapnell, C., L. Pachter, and S. L. Salzberg . 2009. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25:1105-1111.
29. Langmead, B., and S. L. Salzberg . 2012. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9:357-359.
30. Flicek, P., M. R. Amode, D. Barrell, K. Beal, S. Brent, D. Carvalho-Silva, et al. 2012. Ensembl 2012. Nucleic Acids Res. 40:D84-D90.
31. Jones, S., X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
32. Saylors, R. L., III, K. C. Stine, J. Sullivan, J. L. Kepner, D. A. Wall, M. L. Bernstein, et al. 2001. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J. Clin. Oncol. 19:3463-3469.
33. Anderson, M. J. 2001. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 26:32-46.
34. McArdle, B. H., and M. J. Anderson . 2001. Fitting multivariate models to community data: a comment on distance-based redundancy analysis. Ecology 82:290-297.
35. Davidoff, A. M. 2009. Wilms' tumor. Curr. Opin. Pediatr. 21:357-364.
36. Maurer, B. J., M. H. Kang, J. G. Villablanca, J. Janeba, S. Groshen, K. K. Matthay, et al. 2013. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr. Blood Cancer 60:1801-1808.
37. Morgenstern, D. A., M. Marzouki, U. Bartels, M. S. Irwin, G. L. Sholler, J. Gammon, et al. 2014. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr. Blood Cancer 61:128-133.
38. Modak, S., B. H. Kushner, K. Kramer, A. Vickers, I. Y. Cheung, and N. K. Cheung . 2013. Anti-GD2 antibody 3F8 and barley-derived (1 -> 3), (1 -> 4)-beta-glucan: a Phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology 2:e23402.
39. Spunt, S. L., S. A. Grupp, T. A. Vik, V. M. Santana, D. J. Greenblatt, J. Clancy, et al. 2011. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J. Clin. Oncol. 29:2933-2940.
40. Russell, H. V., S. G. Groshen, T. Ara, Y. A. DeClerck, R. Hawkins, H. A. Jackson, et al. 2011. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) study. Pediatr. Blood Cancer 57:275-282.
41. McGregor, L. M., C. F. Stewart, K. R. Crews, M. Tagen, A. Wozniak, J. Wu, et al. 2012. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr. Blood Cancer 58:372-379.
42. Sequist, L. V., R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, et al. 2011. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 22:2616-2624.
43. Mosse, Y. P., M. Laudenslager, L. Longo, K. A. Cole, A. Wood, E. F. Attiyeh, et al. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935.